Back

Residual inflammatory risk appeared related to weight, atherogenic lipid profile and biomarkers of inflammation, but not to glycaemic control in type 1 diabetes

27 August 2022 (10:15 - 11:00)
Organised by:
Congress Presentation Part of: Diabetes and the heart 2 Pathophysiology ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Nicklas J Johansen

Herlev and Gentofte Hospital, Copenhagen (Denmark)

7 More presentations in this session

Presentation thumbnail
Microvascular complications, coronary artery disease and the risk of cardiovascular disease in diabetes patients undergoing coronary angiography: a cohort study from the Western Denmark Heart Registry
Doctor K. Olesen (Aarhus, DK)
Abstract Slides
Presentation thumbnail
Cumulative hyperinsulinemia, hyperglycaemia, and insulin resistance from mid-adolescence through young adulthood with carotid intima-media thickness progression: A 9-year longitudinal study
Associate Professor J. Zachariah (Houston, US)
Abstract Slides
Presentation thumbnail
The exercise tolerance dependence on epicardial fat thickness, right ventricular hypertrophy and right ventricular global function in patients with metabolic syndrome
Assistant Professor E. Argint (Chisinau, MD)
Abstract Slides
Presentation thumbnail
Influence of long-term sodium-glucose cotransporter 2 inhibition on cardiac remodeling in rats with type 1 diabetes mellitus
Mr E. Rodrigues (Botucatu, BR)
Abstract Slides
Presentation thumbnail
Excess mortality in Aspirin and Dipyrone (Metamizole) co-medicated in patients with cardiovascular disease: a nationwide study
Doctor C. Helten (Duesseldorf, DE)
Abstract Slides

Access the full session

Session thumbnail
Diabetes and the heart 2

The Event

Event poster

ESC Congress 2022

27 August 2022 10:15 CET
You may be interested in
thumbnail
Webinar
Prevention of heart failure in diabetic patients at population level
thumbnail
Congress Session
Diabetes, obesity, and heart failure
thumbnail
Webinar
Diabetes and ACS - enhancing post-discharge outcomes after primary PCI

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources